Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
J Zhejiang Univ Sci B
2005 Jul 01;67:656-63. doi: 10.1631/jzus.2005.B0656.
Show Gene links
Show Anatomy links
Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase.
Yang H
,
Zheng S
,
Meijer L
,
Li SM
,
Leclerc S
,
Yu LL
,
Cheng JQ
,
Zhang SZ
.
???displayArticle.abstract???
OBJECTIVE: To screen and evaluate the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 phosphatase.
METHODS: The affinity chromatography purified glutashione-S-transferase/Cdc25A phosphatase fusion protein and Cdc2/cyclin B from the extracts of starfish M phase oocytes are used as the cell cycle-specific targets for screening the antimitotic constituents. We tested 9 extracts isolated from the Chinese medicinal herbs and vegetables including the agents currently used in cancer treatment by measuring the inhibition of Cdc25A phosphatase and Cdc2 kinase activity. The antitumor activity of the extracts was also evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and flow cytometry.
RESULTS: Cdc25A inhibitory activity and antitumor activity are detected in the extracts isolated from three Chinese medicinal herbs Agrimona pilosa; Herba solani lyrati; Galla chinesis.
CONCLUSION: We found three extracts isolated from Chinese medicinal herbs have potential inhibitory activity of Cdc25 phosphatase using a highly specific mechanism-based screen assay for antimitotic drug discovery.
Baratte,
Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase.
1992, Pubmed
Baratte,
Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase.
1992,
Pubmed
Cangi,
Role of the Cdc25A phosphatase in human breast cancer.
2000,
Pubmed
Constantinou,
The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro.
1995,
Pubmed
Farnsworth,
Medicinal plants in therapy.
1985,
Pubmed
Galaktionov,
CDC25 phosphatases as potential human oncogenes.
1995,
Pubmed
Galaktionov,
Cdc25 cell-cycle phosphatase as a target of c-myc.
1996,
Pubmed
Ham,
Naphthoquinone analogs as inactivators of cdc25 phosphatase.
1998,
Pubmed
Hernández,
Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma.
2001,
Pubmed
Hoffmann,
Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition.
1994,
Pubmed
Hotz,
Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes.
1994,
Pubmed
Jinno,
Cdc25A is a novel phosphatase functioning early in the cell cycle.
1994,
Pubmed
Kim,
Involvement of Akt in mitochondria-dependent apoptosis induced by a cdc25 phosphatase inhibitor naphthoquinone analog.
2003,
Pubmed
Lazo,
Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
2001,
Pubmed
Lazo,
Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
2002,
Pubmed
Losso,
In vitro anti-proliferative activities of ellagic acid.
2004,
Pubmed
Loukaci,
Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi.
2001,
Pubmed
Lyon,
Dual-specificity phosphatases as targets for antineoplastic agents.
2002,
Pubmed
Mailand,
Rapid destruction of human Cdc25A in response to DNA damage.
2000,
Pubmed
Mertens-Talcott,
Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells.
2005,
Pubmed
Millar,
p55CDC25 is a nuclear protein required for the initiation of mitosis in human cells.
1991,
Pubmed
Molinari,
Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis.
2000,
Pubmed
Nagata,
An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells.
1991,
Pubmed
Nilsson,
Cell cycle regulation by the Cdc25 phosphatase family.
2000,
Pubmed
Prevost,
Inhibitors of the CDC25 phosphatases.
2003,
Pubmed
Pu,
Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione.
2002,
Pubmed
Sadhu,
Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2.
1990,
Pubmed
Sohn,
Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones.
2003,
Pubmed
Tamura,
Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue.
2000,
Pubmed
Twentyman,
Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay.
1989,
Pubmed
Yang,
[The antitumor activity of elemene is associated with apoptosis].
1996,
Pubmed
Zheng,
Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention.
1997,
Pubmed
